A Tumor-Environment-Responsive Nanocarrier That Evolves Its Surface Properties upon Sensing Matrix Metalloproteinase-2 and Initiates Agglomeration to Enhance T2 Relaxivity for Magnetic Resonance Imaging
- 16 September 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (5), 1970-1974
- https://doi.org/10.1021/mp2001999
Abstract
We designed and synthesized a modified ferritin as a tumor-environment-responsive nanocarrier. We found that this nanocarrier could evolve its surface properties upon sensing a tumor-associated protease, matrix metalloproteinase-2 (MMP-2), which initiated agglomeration, resulting in the enhancement of T(2) relaxivity for magnetic resonance imaging (MRI). The designed ferritin contained a triad of modifiers composed of (i) a "sensing" segment (substrate peptide of MMP-2), (ii) "hydrophobic" segments and (iii) a "hydrophilic" segment of polyethylene glycol (PEG). The hydrophilic segment ensured the particles' monodispersibility in aqueous conditions. In the presence of MMP-2 activity, the "sensing" segment was cleaved by the enzyme and its submerged "hydrophobic" segments were exposed on the surface, resulting in the initiation of aggregation. Because ferritin contains ferrihydrite in its inner space, this multimerization resulted in the enhancement of T(2) relaxivity, suggesting that this nanocarrier may be useful as a contrast agent in MRI.Keywords
This publication has 33 references indexed in Scilit:
- Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug DeliveryMolecular Pharmaceutics, 2009
- Recent progress in tumor pH targeting nanotechnologyJournal of Controlled Release, 2008
- Tumour endoproteases: the cutting edge of cancer drug delivery?British Journal of Pharmacology, 2008
- Molecular aspects of tumour hypoxiaMolecular Oncology, 2008
- Sheddable Coatings for Long-Circulating NanoparticlesPharmaceutical Research, 2007
- Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalizationMicrovascular Research, 2007
- Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targetingJournal of Controlled Release, 2006
- Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancersBiochimie, 2005
- Tumor imaging by means of proteolytic activation of cell-penetrating peptidesProceedings of the National Academy of Sciences, 2004
- In vivo molecular target assessment of matrix metalloproteinase inhibitionNature Medicine, 2001